晚期NSCLC一线Nivo-Ipi治疗6个月后停药对比持续治疗的四年结局:随机III期IFCT-1701 DICIPLE试验
该随机开放标签非劣效III期试验入组初治转移性NSCLC患者,经6个月Nivo-Ipi诱导后疾病控制者随机分为继续治疗或停药、进展时再挑战。因该免疫联合未在欧洲申报而提前终止,仅71例随机。4年随访显示停药组无生存损害,3-5级治疗相关不良事件更少,生活质量恶化更晚。
要点
- 6个月Nivo-Ipi后停药未显示4年生存损害。
- 停药组3-5级治疗相关不良事件率23.5%,低于持续组的54.3%。
- 停药组至明确生活质量恶化时间未达到,持续组为15.5个月。
核心结论
- 在经6个月Nivo-Ipi诱导后疾病控制的转移性NSCLC患者中,停药至进展再挑战在4年随访时未显示生存损害,且严重免疫相关不良事件更少、生活质量恶化更延迟。
研究设计与样本
- 随机、开放标签、非劣效III期试验,入组初治转移性NSCLC患者(18-75岁,ECOG PS 0-1,无可用基因组变异)。
- 入组265例,经6个月Nivo(3 mg/kg 每2周)联合Ipi(1 mg/kg 每6周)诱导后疾病控制者71例随机至持续治疗组(n=36)或停药组(n=35)。
- 因该免疫联合缺乏欧洲申报,试验提前中断;主要终点为无进展生存期(PFS)。
主要发现
- 中位PFS随访47.8个月(95%CI 43.1-51.0)。
- 符合方案人群中,持续治疗组中位PFS为18.7个月(95%CI 7.1-37.1),停药组未达到(95%CI 16.1-NR)。
- 持续治疗组中位OS为55.5个月(95%CI 32.4-NR),停药组未达到;18个月OS分别为80.6%(95%CI 63.5-90.2)和93.8%(95%CI 77.3-98.4)。
- 3-5级治疗相关不良事件率持续治疗组为54.3%,停药组为23.5%。
- 至明确生活质量恶化的中位时间持续治疗组为15.5个月(95%CI 10.0-NR),停药组未达到(HR=0.36,95%CI 0.14-0.92,p=0.03)。
关键数值与推荐
- 疾病控制者经6个月Nivo(3 mg/kg 每2周)联合Ipi(1 mg/kg 每6周)诱导后可考虑停药,进展时再挑战。
临床怎么用
- 对6个月Nivo-Ipi诱导后疾病控制的转移性NSCLC患者,停药策略可减少严重免疫相关不良事件并延迟生活质量恶化,且4年随访未显示生存损害。
局限性
- 试验因缺乏欧洲申报而提前中断,随机样本量仅71例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Optimal first-line immunotherapy duration in metastatic NSCLC with controlled disease remains unclear. We evaluated 6-month nivolumab-ipilimumab (Nivo-Ipi) in patients with disease control (DC). METHODS: This randomized, open-label, noninferiority trial enrolled treatment-naive patients with metastatic NSCLC (aged 18-75 y, Eastern Cooperative Oncology Group performance status 0-1, no actionable genomic alterations). After 6-month induction treatment with Nivo (3 mg/kg biweekly) plus Ipi (1 mg/kg every 6 wk), patients with DC were randomized to continue treatment or stop and resume at disease progression. The primary outcome was progression-free survival (PFS). RESULTS: Among 265 patients enrolled, 71 were randomized to the continuation control arm (n = 36) or to the experimental arm (n = 35), with trial premature interruption because of the lack of European filing for the immunotherapy combination. Median PFS follow-up was 47.8 months (95% confidence interval [CI]: 43.1-51.0). In the per-protocol population, median PFS was 18.7 months (95% CI: 7.1-37.1) in the continuation arm versus not reached (NR) (95% CI: 16.1-NR) in the experimental arm. Median OS was 55.5 months (95% CI: 32.4-NR) in the continuation arm versus NR in the experimental group. The 18-month OS was 80.6% (95% CI: 63.5-90.2) and 93.8% (95% CI: 77.3-98.4), respectively. Grade 3 to 5 treatment-related adverse event rates were higher in the continuation arm (54.3% versus 23.5%). Median time until definitive quality-of-life deterioration was 15.5 months (95% CI: 10.0-NR) for the continuation arm but NR in the experimental arm (hazard ratio = 0.36, 95% CI: 0.14-0.92, p = 0.03). CONCLUSIONS: Stopping Nivo-Ipi combination at 6 months in DC patients demonstrated no survival harm at 4 years, reduced severe immune-related adverse events, and delayed quality-of-life deterioration.
引用
- Zalcman G, Madroszyk A, Guenzi E, et al. Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial. J Thorac Oncol. 2026. PMID: 41690366. doi:10.1016/j.jtho.2026.103609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。